Updated Jul 16, 2026
Halladay Benjamin has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $79K.
Benjamin Halladay is the Chief Financial Officer of Esperion Therapeutics, Inc., a pharmaceutical company focused on developing non-statin medicines for cholesterol management. He has been involved in the company's financial operations and reporting.
| Role | Chief Financial Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-13 | ESPR | Esperion Therapeutics, Inc. | D — Derivative transaction | 705.4K | — | |
| 2026-06-18 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 10.8K | $3.15 | $34K |
| 2026-03-18 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 6.4K | $2.71 | $17K |
| 2026-03-16 | ESPR | Esperion Therapeutics, Inc. | A — Grant or award | 247.4K | $0.00 | |
| 2025-09-17 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 7.0K | $2.81 | $20K |
| 2025-07-17 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 11 | $1.11 | $12 |
| 2024-12-18 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 3.2K | $2.42 | $8K |
Benjamin Halladay is the Chief Financial Officer of Esperion Therapeutics, Inc., a pharmaceutical company focused on developing non-statin medicines for cholesterol management. He has been involved in the company's financial operations and reporting.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($79K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Halladay Benjamin profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.